Researchers have noticed that frequency of Lin− HLA-DRlow/− CD11b+ CD33+ total MDSC is associated with the response of atezolizumab in patients with advanced NSCLC. The gene discussed is ITGAM; the disease is non-small cell lung carcinoma.